Has Pete Fong, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,750 in general payments to Pete Fong, MD across 76 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pete Fong, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pete Fong, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pete Fong, MD

Cardiovascular Disease · Nashville, TNNPI 1912060906

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,277 of the $8,750 with a category attached, or 60.3%. 9 manufacturers reported payments, led by Medtronic at 53.1% of the total. 2025 is the largest year on record at $4,948, more than ten times the $121 reported in 2020.

$8,750in general payments, 2019–2025

Across 76 payments — averaging $115.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$5K
Boston Scientific$2K
Thrombolex, Inc.$766
Abiomed$472
Inari Medical, Inc.$422
Penumbra, Inc.$279
plus $434 from 3 others

$612,386in research payments, 2019–2025

Across 69 payments — averaging $8875.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$515K
Inari Medical, Inc.$42K
Recor Medical Inc$34K
EKOS Corporation$11K
Boston Scientific$10K

What the payments were for

Travel & lodging$3,47340%
Food & beverage$5,27760%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	43	$4,645
Boston Scientific	11	$1,730
Thrombolex, Inc.	3	$766
Abiomed	5	$472
Inari Medical, Inc.	5	$422
Penumbra, Inc.	2	$279
Angiodynamics, Inc.	4	$221
Abbott	2	$185
ZOLL Circulation Inc	1	$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,750 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee →

Medicare billing

Part B allowed, 2024

$186,511

Medicare patients

704

Services billed

1,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	170	$229,621
Repatha SureclickEvolocumab	114	$124,744
XareltoRivaroxaban	79	$121,861
EntrestoSacubitril/Valsartan	37	$69,661
JardianceEmpagliflozin	42	$52,158
Repatha PushtronexEvolocumab	37	$28,089
FarxigaDapagliflozin Propanediol	22	$25,955
Praluent PenAlirocumab	21	$20,753
BrilintaTicagrelor	17	$16,660
Atorvastatin Calcium	431	$4,754
Nifedipine ErNifedipine	149	$3,824
Losartan Potassium	313	$3,487
Carvedilol	376	$3,178
Diltiazem 24hr Er (Cd)Diltiazem Hcl	79	$2,813
Metoprolol Succinate	179	$2,787

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Nashville

Christopher EllisNashville$527K
Joann LindenfeldNashville$270K
Andrew ZurickNashville$231K
Mark ZenkerNashville$225K
George CrossleyNashville$197K
Joel PharesNashville$171K
Arvindh KanagasundramNashville$161K
Jessica HustonNashville$109K
Joshua BeckmanNashville$106K
Travis RichardsonNashville$87K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →